The short answer
He and colleagues published a systematic review and meta-analysis in JAMA Internal Medicine in 2022 examining the association of GLP-1 receptor agonist use with risk of gallbladder and biliary diseases. The pooled analysis that turned scattered trial observations into an estimate.
Key facts
- Study
- He 2022, JAMA Intern Med (PMID 35344001)
- Design
- Systematic review and meta-analysis
- Outcome
- Gallbladder and biliary diseases
- Why pooled
- Events too infrequent in single trials
- Mechanism identified
- CCK suppression (Rehfeld 2018)
- Tirzepatide-specific
- Zeng 2023 (PMID 37908750)
Why individual trials could not answer this
Gallbladder events occur in a small percentage of participants. A trial powered to detect a difference in weight reduction is not powered to detect a difference in an outcome affecting a few per cent, so individual trials produce numbers too small to interpret, a handful of events in each arm, consistent with almost anything.
What pooling achieves
Combining events across many randomised trials produces enough of them to estimate a difference with usable precision, while retaining randomisation. That is the key advantage over an observational cohort: confounding by indication does not arise, because assignment was random within each contributing trial.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Why this signal was noticed at all
Because it appeared consistently. A scattering of gallbladder events across many trials of the same drug class, in the same direction, is the pattern that prompts a formal pooled analysis. Isolated events in one trial would not have.
The tirzepatide-specific question
Zeng and colleagues addressed pancreatitis and gallbladder or biliary disease with tirzepatide specifically in a systematic review and meta-analysis in Frontiers in Endocrinology in 2023. Compound-specific analyses matter because this class has already proven non-uniform. The oral contraceptive interaction is tirzepatide-specific and not shared by the pure GLP-1 agonists.
How to read a pooled safety estimate
As a relative measure attached to an absolute baseline. A relative increase in an infrequent event remains an infrequent event, and a relative figure quoted without the underlying rate conveys almost nothing about magnitude. This is the most common way safety meta-analyses are misreported.
What it does not describe
Anything supplied on this site. These analyses pool randomised trials of licensed and investigational medicines administered under clinical supervision. No research material is a GLP-1 receptor agonist or is covered by any of this evidence.
Frequently asked questions
Why was a meta-analysis needed?
Gallbladder events are too infrequent for a single weight-loss trial to detect a difference. Pooling produces enough events to estimate one.
Is pooled randomised data better than a cohort?
For this question, yes on one axis. Randomisation within each trial removes confounding by indication, which cohort studies cannot.
How should a relative increase be read?
Against the absolute baseline rate. A relative increase in an infrequent event is still infrequent, and the relative figure alone conveys little.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedHe L et al., Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis. JAMA Intern Med 2022 (PMID 35344001)pubmed.ncbi.nlm.nih.gov
- PubMedZeng Q et al., Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease). Front Endocrinol 2023 (PMID 37908750)pubmed.ncbi.nlm.nih.gov
- PubMedRehfeld JF et al. Scand J Gastroenterol 2018 (PMID 30449207)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- The Gallbladder Case Is Unusually CompleteObservation, then mechanism, then quantification. Most safety signals never get all three - which is why this one is worth studying as a template.
- What Happens to Bone When Load Comes OffBone responds to mechanical loading, so losing mass reduces the stimulus that maintains it. A 2025 critical appraisal examines what the medications add.
- Why Orthopaedic Surgeons Started Paying AttentionA 2025 review in a musculoskeletal journal covers GLP-1 agonists and orthopaedic care - a specialty encountering these drugs from a different direction.
- How Many People Are Still Taking It a Year LaterTrials report what happens to people who stay on treatment. Real-world persistence with GLP-1 therapies is the variable that decides whether that matters.
- Why a Drug Works Less Well Than Its Trial SaidEfficacy is performance under trial conditions; effectiveness is what happens in practice. The gap is predictable, and it has identifiable causes.